MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation
MAGED4 is upregulated in hepatocellular carcinoma and promotes tumor progression by activating the JAK2/STAT3 pathway.
Asset / Drug
Drug and asset intelligence for MAGED4 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.